Developer docs
API playgroundTry for free, no card

Search company profiles

MagQu

Full company profile

uuid000pqnu

Namestring
MagQu
Legal namestring
MagQu Co. Ltd
Websiteurl
magqu.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

MagQu Co., Ltd. (磁量生技股份有限公司) is a Taiwan-based, privately held biotechnology company founded in 2008 and headquartered in New Taipei City. The company develops and commercializes ImmunoMagnetic Reduction (IMR) technology — an ultra-sensitive bioassay platform that uses functionalized Fe3O4 magnetic nanoparticles conjugated with antibodies to bind target biomarkers, with quantification achieved by measuring changes in AC magnetic susceptibility using a Superconducting Quantum Interference Device (SQUID) detector. MagQu claims to have developed the world's first CE-IVD certified Alzheimer's disease blood test, with three core IMR reagent products (Amyloid β 1-40, Amyloid β 1-42, and Tau protein) plus supporting analyzers (XacPro-S, MagQuan V, XacQuan V), magnetic beads, nucleic acid extraction kits, and OEM/ODM services. The platform is positioned as a non-invasive alternative to spinal taps and PET imaging for early Alzheimer's detection, with claimed picomolar-level sensitivity (1-200 pg/mL for Aβ1-40; 1-100 pg/mL for Aβ1-42 and Tau) and 5-hour turnaround.

The company's primary customer segments are healthcare providers and clinical research institutions, served through direct institutional sales in Taiwan and through channel/distribution partnerships in Europe and the United States. Revenue is generated through IVD reagent kit sales, analyzer/instrument hardware sales, magnetic bead and separator sales, OEM/ODM services for kits and instruments, and contract magnetic concentration measurement services. Pricing is quote-based and not publicly disclosed. Clinical validation has been conducted through partnerships with four major Taiwanese medical centers (National Taiwan University Hospital, Shuang Ho Hospital, Renai Hospital, En Chu Kong Hospital) covering 400+ Phase II/III patient cases with reported 80% diagnostic accuracy. International commercial expansion is enabled by CE-IVD certification and channel relationships with European biotech partners, UK-based Cerba Research, US-based St. Joseph's Hospital and Medical Center, and Arizona State University. The company holds more than 50 granted patents across North America, Japan, the EU, China, and Taiwan covering the core IMR platform, magnetic bead conjugation chemistry, and specific biomarker reagent formulations.

Short descriptiontext

MagQu is a Taiwan-based biotechnology company that develops ultra-sensitive blood-based diagnostic tests using proprietary ImmunoMagnetic Reduction (IMR) and SQUID detection technology, primarily serving hospitals, clinical research institutions, and diagnostic laboratories in Alzheimer's disease, oncology, and life science research markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew City, United States
HQ citystring
New City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in vitro diagnostics, immunoassay reagents, magnetic susceptibility analysis, Alzheimer's blood test, SQUID bioassay instruments
Industry5 codes
PRIMARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAHAAAL
Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code4 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
  • Medical Laboratories621511
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
In Vitro Diagnostics (IVD) and Immunoassay Reagents
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1IVD Reagent Sales
TypeOne Time License
Description

Sale of IMR reagent kits for detecting specific biomarkers including Aβ1-40, Aβ1-42, Tau protein, AFP, and CEA. Sold in kit format with catalog numbers (e.g., MF-AB0-006B, MF-AB2-006B, MF-TAU-006B) for clinical and research use.

magqu.com
2Analyzer/Instrument Sales
TypeHardware Sales
Description

Sale of magnetic immunoassay analyzers (XacPro-S, MagQuan V, XacQuan V) and magnetic separators (Magdorf). Instruments provide the platform for running IMR assays.

magqu.com
3Magnetic Beads and Separators
TypeHardware Sales
Description

Sale of magnetic beads (Qbeads-Carboxyl, Magnetic Fluid-Carboxyl) and magnetic separators for research and diagnostic applications. Includes labeling kits for custom conjugation.

magqu.com
4Customized Instrument OEM/ODM Services
TypeProfessional Services
Description

Instrument customization services and OEM/ODM for IMR assay kit development, magnetic beads development, and antibody manufacturing for partners.

magqu.com
5Magnetic Concentration Quantification Service
TypeProfessional Services
Description

Contract testing services for magnetic concentration measurements using proprietary analyzers.

magqu.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

MagQu develops, manufactures, and sells in-vitro diagnostic (IVD) reagent kits and analyzer instruments built on its proprietary ImmunoMagnetic Reduction (IMR) platform for ultra-sensitive detection of blood biomarkers, including Aβ1-40, Aβ1-42, and Tau protein for early Alzheimer's disease diagnosis. The product portfolio includes CE-IVD and Taiwan FDA-cleared reagent kits, SQUID-based Magnetic Immunoassay Analyzers, magnetic concentration analyzers, functionalized magnetic beads, magnetic separators, and nucleic acid extraction kits sold directly to hospitals, research institutions, and diagnostic laboratories. Custom OEM/ODM services and contract magnetic concentration quantification services supplement the product offering.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 80% clinical accuracy in distinguishing mild cognitive impairment and early Alzheimer's disease patients
+4 more records
Product overview1 text field

MagQu is a biotechnology company specializing in ImmunoMagnetic Reduction (IMR) technology for ultra-sensitive biomarker detection. The product portfolio consists of: (1) Analyzer instruments including the XacPro-S SQUID-based Magnetic Immunoassay Analyzer for clinical IMR measurements, the MagQuan V rapid magnetic concentration analyzer (30 sec/sample), and the XacQuan V frequency-dependent magnetic susceptibility analyzer (50-24900 Hz bandwidth); (2) IMR Reagents including Amyloid β 1-40, Amyloid β 1-42, and Tau Protein reagents for Alzheimer's disease diagnosis, with CE-IVD and Taiwan FDA certifications; (3) Magnetic beads including Qbeads-Carboxyl (~1 μm) and Magnetic Fluid-Carboxyl nanoparticles (50-60 nm) for molecular conjugation; (4) Supporting products including the Magdorf 8-well magnetic separator, Blood gDNA Extraction Kit, Virus DNA/RNA Extraction Kit, Cell Nucleic Acid Extraction Kit, and Qbeads-Carboxyl Labeling Kit. The IMR platform works by conjugating detection antibodies to Fe3O4 magnetic nanoparticles, which form clusters upon binding target biomarkers, reducing AC magnetic susceptibility in proportion to biomarker concentration.

Product and service19 records
1XacPro-S Magnetic Immunoassay Analyzer
CategoryClinical immunoassay instrument
Description

SQUID-based immunoassay analyzer that measures AC magnetic susceptibility for IMR bioassays, enabling ultra-high-sensitivity quantification of biomarkers such as Aβ1-40, Aβ1-42, and Tau protein in human fluid specimens. Designed for clinical and research laboratories running MagQu's IMR reagent portfolio.

2MagQuan V Magnetic Concentration Analyzer
CategoryResearch and industrial analyzer
Description

Rapid magnetic concentration measurement instrument that measures AC magnetization intensity for samples at roughly 30 seconds per sample, covering solid and liquid samples with volumes up to 5 mL without pretreatment. Used by industrial, materials, and research customers for fast magnetic concentration analysis.

3XacQuan V Frequency-Dependent Magnetic Susceptibility Analyzer
CategoryResearch and industrial analyzer
Description

Frequency-dependent magnetic susceptibility analyzer that measures real and imaginary components of AC magnetic susceptibility across a 50–24900 Hz bandwidth for analyzing magnetic concentration and material properties. Targeted at industrial QC, materials research, and life science research laboratories.

4MagQu Amyloid β 1-40 (Aβ1-40) IMR Reagent
CategoryIVD reagent (Alzheimer's disease)
Description

ImmunoMagnetic Reduction reagent (MF-AB0-006B) for quantitative detection of Amyloid β 1-40 protein in human plasma with an analytical range of 1–200 pg/mL. Uses ~50 nm Fe3O4 magnetic particles conjugated with anti-Aβ1-40 antibodies; assists in the diagnosis of Alzheimer's disease. CE-IVD and Taiwan FDA cleared for IVD use.

5MagQu Amyloid β 1-42 (Aβ1-42) IMR Reagent
CategoryIVD reagent (Alzheimer's disease)
Description

ImmunoMagnetic Reduction reagent (MF-AB2-006B) for quantitative detection of Amyloid β 1-42 protein in human plasma with an analytical range of 1–100 pg/mL. Designed to assist in the diagnosis of Alzheimer's disease by detecting a major component of amyloid plaques. CE-IVD and Taiwan FDA cleared for IVD use.

6MagQu Tau Protein IMR Reagent
CategoryIVD reagent (neurodegenerative disease)
Description

ImmunoMagnetic Reduction reagent (MF-TAU-006B) for quantitative detection of Tau protein in human plasma with an analytical range of 1–100 pg/mL. Associated with Alzheimer's, Pick's, Parkinson's, and other neurodegenerative conditions. CE-IVD and Taiwan FDA cleared for IVD use.

7Aβ1-40 Protein Control Solution
CategoryQuality control reagent
Description

Low and high concentration quality control solutions used as standards for MagQu's Aβ1-40 IMR Reagent (MF-AB0-006B). Supplied alongside the reagent as part of the clinical IMR assay workflow.

8Qbeads-Carboxyl Magnetic Beads
CategoryLife science research reagent (magnetic beads)
Description

Carboxyl-functionalized magnetic beads (~1 μm diameter) with a single-crystal Fe3O4 core and dextran coating, used for covalent conjugation of antibodies, proteins, peptides, or DNA via EDC activation. Sold to life science research laboratories for custom assay development.

9Magnetic Fluid-Carboxyl Nanoparticles
CategoryLife science research reagent (magnetic nanoparticles)
Description

Carboxyl-functionalized magnetic nanoparticles (50–60 nm diameter, 8 mg-Fe/mL concentration) with a dextran-coated Fe3O4 core, used for biospecies separation, biomedical imaging, and bioassay development. Supplied to research laboratories and OEM partners.

10Magdorf Magnetic Separator
CategoryLaboratory instrument (magnetic separator)
Description

Eight-well magnetic separator for 1.5 mL microcentrifuge tubes providing strong magnetism for fast collection of micron-size magnetic beads, used in bead-based nucleic acid extraction and immunoprecipitation workflows in research labs.

11Blood gDNA Extraction Kit
CategoryMolecular biology kit
Description

Manual genomic DNA extraction kit from blood samples using magnetic particles, providing high-yield, low-cost purified gDNA suitable for Real-Time PCR, PCR, and other molecular experiments. 96 reactions per kit, sold to research and clinical molecular laboratories.

12Virus DNA/RNA Extraction Kit (manual)
CategoryMolecular biology / IVD kit
Description

Manual extraction kit for viral DNA or RNA from cell-free samples using magnetic particles, with DNA/RNA separable by user-added DNase or RNase. Marketed for in vitro diagnostic use by clinical and research laboratories.

13Cell Nucleic Acid Extraction Kit
CategoryMolecular biology kit
Description

Manual extraction kit for total nucleic acids from cells using magnetic particles, yielding purified nucleic acids suitable for Real-Time PCR, PCR, and other molecular experiments. Sold to research laboratories.

14Qbeads-Carboxyl Labeling Kit
CategoryLife science research kit
Description

Complete kit for covalently conjugating antibodies, peptides, or DNA with primary amine groups onto carboxyl-functionalized Qbeads, used for immunoprecipitation, chromatin immunoprecipitation, and pull-down assays in research laboratories.

15IMR Assay Kit OEM/ODM Customization Service
CategoryOEM/ODM service
Description

OEM/ODM customization services for IMR assay kit development, enabling partners to leverage MagQu's IMR platform for their own biomarker assays. Sold to diagnostic and biotech partners.

16Magnetic Beads OEM/ODM Development Service
CategoryOEM/ODM service
Description

Custom development of functionalized magnetic beads for OEM/ODM partners, including bead design, surface chemistry, and application-specific conjugation services. Sold to life science and diagnostic partners.

17Antibody OEM/ODM Service
CategoryOEM/ODM service
Description

Custom antibody manufacturing and OEM/ODM antibody services for partners, supporting IMR assay and magnetic bead development workflows. Sold to diagnostic and research partners.

18Magnetic Concentration Quantification Service
CategoryContract testing service
Description

Contract magnetic concentration measurement service performed by MagQu on customer samples using MagQu's proprietary analyzers, including applications such as lubricant iron content monitoring, magnetic fluid concentration, and steel/powder metallurgy QC. Sold to industrial and research customers.

19Instrument Customization Service
CategoryOEM/ODM / engineering service
Description

Instrument customization services adapting MagQu's XacPro-S, MagQuan V, XacQuan V, and Magdorf platforms for partner-specific analytical workflows. Sold to OEM/ODM partners and large institutional customers.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-01
Description

Cerba Research, a UK-based clinical research organization, acknowledged the efficacy of MagQu's immunomagnetic reduction (IMR) blood test for diagnosing early Alzheimer's disease in July 2021. The partnership focuses on developing blood-based biomarkers for early diagnosis of Alzheimer's disease, with reference to published studies showing elevated plasma Aβ42 and t-tau levels correlate with later cognitive decline in patients with mild cognitive impairment.

2European Biotech/Medical Partners (Continental Europe)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Strategic collaboration with European biotech and medical companies for market entry into continental Europe. The partnership leverages MagQu's CE-IVD certified Alzheimer's blood test products to serve the European clinical diagnostics market. This followed recognition as the world's first CE-IVD certified Alzheimer's blood test and significant international attention from US, European, and Japanese pharmaceutical companies seeking clinical research and commercial partnerships.

magqu.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

US clinical application partnership for neurodegenerative disease blood testing, including development and validation of IMR-based diagnostics in a clinical setting. Plans include establishment of a CLIA-certified reference laboratory for providing IMR blood test services in the US market.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research collaboration with Arizona State University for clinical research partnerships and application development of neurodegenerative disease blood tests. ASU's research capabilities complement MagQu's IMR technology platform for advancing Alzheimer's disease diagnostics.

5National Taiwan University Hospital, Shuang Ho Hospital, Renai Hospital, En Chu Kong Hospital
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial partnerships with major Taiwanese medical institutions for validation of Alzheimer's disease blood screening platform. Completed Phase II and Phase III clinical trials involving 400+ patient cases, achieving 80% diagnostic accuracy. Results supported Taiwan FDA (TFDA) registration applications for Class III medical device approval.

magqu.com
Peers10 records
TypeEmerging player
Description

PerkinElmer's diagnostics and life sciences segments provide biomarker detection reagents and instruments overlapping with MagQu's analyzer and reagent portfolio, particularly in clinical and translational research.

TypeBroad incumbent
Description

Roche's Elecsys Alzheimer's disease plasma assays (pTau217, Aβ42) run on the globally installed cobas analyzer base, representing a much larger-scale incumbent that MagQu would compete against for hospital adoption.

TypeDirect peer
Description

C2N's PrecivityAD blood test for Alzheimer's diagnosis is the most direct US-market competitor, and its CLIA-certified reference lab service model parallels MagQu's planned St. Joseph's CLIA partnership strategy.

TypeBroad incumbent
Description

Siemens' ADVIA Centaur and Atellica immunoassay platforms address Alzheimer's and oncology biomarker testing through a global installed base, overlapping with MagQu's clinical diagnostic use cases.

TypeDirect peer
Description

Quanterix's Simoa single-molecule array technology provides ultra-sensitive blood-based biomarker detection, directly comparable to MagQu's IMR platform in pursuit of picomolar-level quantification of neurodegeneration and oncology biomarkers.

TypeBroad incumbent
Description

Bio-Techne offers protein biomarker assay kits and magnetic bead-based research reagents through its ProteinSimple and R&D Systems brands, overlapping with MagQu's life-science research and IMR reagent offerings.

7ADx NeuroSciences
TypeEmerging player
Description

ADx NeuroSciences develops and licenses high-quality Alzheimer's biomarker antibodies and assays, overlapping with MagQu's IMR reagent portfolio as a focused emerging player in neurodegeneration diagnostics.

TypeDirect peer
Description

Fujirebio's Lumipulse G pTau217/β-amyloid 1-42 plasma assays are FDA-cleared blood-based Alzheimer's diagnostics with overlapping biomarker menu and clinical positioning to MagQu's CE-IVD Alzheimer's reagents.

TypeRegional player
Description

Sysmex is a Japan-headquartered diagnostics and life-sciences company with strong Asia-Pacific distribution and a hematology/immunoassay footprint relevant to MagQu's Japan presence and broader Asian commercial strategy.

10Abbott Diagnostics
TypeBroad incumbent
Description

Abbott's ARCHITECT and Alinity immunoassay systems run biomarker panels relevant to neurodegeneration and oncology, representing broad incumbent competition for clinical diagnostic menu share.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MagQu

In Vitro Diagnostics (IVD) and Immunoassay Reagentsmagqu.com

MagQu is a Taiwan-based biotechnology company that develops ultra-sensitive blood-based diagnostic tests using proprietary ImmunoMagnetic Reduction (IMR) and SQUID detection technology, primarily serving hospitals, clinical research institutions, and diagnostic laboratories in Alzheimer's disease, oncology, and life science research markets.

What MagQu does

MagQu Co., Ltd. (磁量生技股份有限公司) is a Taiwan-based, privately held biotechnology company founded in 2008 and headquartered in New Taipei City. The company develops and commercializes ImmunoMagnetic Reduction (IMR) technology — an ultra-sensitive bioassay platform that uses functionalized Fe3O4 magnetic nanoparticles conjugated with antibodies to bind target biomarkers, with quantification achieved by measuring changes in AC magnetic susceptibility using a Superconducting Quantum Interference Device (SQUID) detector. MagQu claims to have developed the world's first CE-IVD certified Alzheimer's disease blood test, with three core IMR reagent products (Amyloid β 1-40, Amyloid β 1-42, and Tau protein) plus supporting analyzers (XacPro-S, MagQuan V, XacQuan V), magnetic beads, nucleic acid extraction kits, and OEM/ODM services. The platform is positioned as a non-invasive alternative to spinal taps and PET imaging for early Alzheimer's detection, with claimed picomolar-level sensitivity (1-200 pg/mL for Aβ1-40; 1-100 pg/mL for Aβ1-42 and Tau) and 5-hour turnaround.

The company's primary customer segments are healthcare providers and clinical research institutions, served through direct institutional sales in Taiwan and through channel/distribution partnerships in Europe and the United States. Revenue is generated through IVD reagent kit sales, analyzer/instrument hardware sales, magnetic bead and separator sales, OEM/ODM services for kits and instruments, and contract magnetic concentration measurement services. Pricing is quote-based and not publicly disclosed. Clinical validation has been conducted through partnerships with four major Taiwanese medical centers (National Taiwan University Hospital, Shuang Ho Hospital, Renai Hospital, En Chu Kong Hospital) covering 400+ Phase II/III patient cases with reported 80% diagnostic accuracy. International commercial expansion is enabled by CE-IVD certification and channel relationships with European biotech partners, UK-based Cerba Research, US-based St. Joseph's Hospital and Medical Center, and Arizona State University. The company holds more than 50 granted patents across North America, Japan, the EU, China, and Taiwan covering the core IMR platform, magnetic bead conjugation chemistry, and specific biomarker reagent formulations.

MagQu firmographics

Firmographics
Name
MagQu
Legal name
MagQu Co. Ltd
Website
https://magqu.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
MagQu is a Taiwan-based biotechnology company that develops ultra-sensitive blood-based diagnostic tests using proprietary ImmunoMagnetic Reduction (IMR) and SQUID detection technology, primarily serving hospitals, clinical research institutions, and diagnostic laboratories in Alzheimer's disease, oncology, and life science research markets.
Ownership category
akta.pro rank

MagQu industry classification

Industry
Product category
In Vitro Diagnostics (IVD) and Immunoassay Reagents
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511), Medical Equipment and Supplies Manufacturing (3391)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAHAAAL
Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • In vitro diagnostics
  • Immunoassay reagents
  • Magnetic susceptibility analysis
  • Alzheimer's blood test
  • SQUID bioassay instruments

Where MagQu is headquartered

Location

Headquarters

HQ city
New City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

MagQu business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

  1. IVD Reagent Sales: Sale of IMR reagent kits for detecting specific biomarkers including Aβ1-40, Aβ1-42, Tau protein, AFP, and CEA. Sold in kit format with catalog numbers (e.g., MF-AB0-006B, MF-AB2-006B, MF-TAU-006B) for clinical and research use.
  2. Analyzer/Instrument Sales: Sale of magnetic immunoassay analyzers (XacPro-S, MagQuan V, XacQuan V) and magnetic separators (Magdorf). Instruments provide the platform for running IMR assays.
  3. Magnetic Beads and Separators: Sale of magnetic beads (Qbeads-Carboxyl, Magnetic Fluid-Carboxyl) and magnetic separators for research and diagnostic applications. Includes labeling kits for custom conjugation.
  4. Customized Instrument OEM/ODM Services: Instrument customization services and OEM/ODM for IMR assay kit development, magnetic beads development, and antibody manufacturing for partners.
  5. Magnetic Concentration Quantification Service: Contract testing services for magnetic concentration measurements using proprietary analyzers.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

MagQu product offering

Product offering

Core offering

MagQu develops, manufactures, and sells in-vitro diagnostic (IVD) reagent kits and analyzer instruments built on its proprietary ImmunoMagnetic Reduction (IMR) platform for ultra-sensitive detection of blood biomarkers, including Aβ1-40, Aβ1-42, and Tau protein for early Alzheimer's disease diagnosis. The product portfolio includes CE-IVD and Taiwan FDA-cleared reagent kits, SQUID-based Magnetic Immunoassay Analyzers, magnetic concentration analyzers, functionalized magnetic beads, magnetic separators, and nucleic acid extraction kits sold directly to hospitals, research institutions, and diagnostic laboratories. Custom OEM/ODM services and contract magnetic concentration quantification services supplement the product offering.

Product overview

MagQu is a biotechnology company specializing in ImmunoMagnetic Reduction (IMR) technology for ultra-sensitive biomarker detection. The product portfolio consists of: (1) Analyzer instruments including the XacPro-S SQUID-based Magnetic Immunoassay Analyzer for clinical IMR measurements, the MagQuan V rapid magnetic concentration analyzer (30 sec/sample), and the XacQuan V frequency-dependent magnetic susceptibility analyzer (50-24900 Hz bandwidth); (2) IMR Reagents including Amyloid β 1-40, Amyloid β 1-42, and Tau Protein reagents for Alzheimer's disease diagnosis, with CE-IVD and Taiwan FDA certifications; (3) Magnetic beads including Qbeads-Carboxyl (~1 μm) and Magnetic Fluid-Carboxyl nanoparticles (50-60 nm) for molecular conjugation; (4) Supporting products including the Magdorf 8-well magnetic separator, Blood gDNA Extraction Kit, Virus DNA/RNA Extraction Kit, Cell Nucleic Acid Extraction Kit, and Qbeads-Carboxyl Labeling Kit. The IMR platform works by conjugating detection antibodies to Fe3O4 magnetic nanoparticles, which form clusters upon binding target biomarkers, reducing AC magnetic susceptibility in proportion to biomarker concentration.

Differentiator

Problem solved

Functional benefit

Products and services

  • XacPro-S Magnetic Immunoassay Analyzer SQUID-based immunoassay analyzer that measures AC magnetic susceptibility for IMR bioassays, enabling ultra-high-sensitivity quantification of biomarkers such as Aβ1-40, Aβ1-42, and Tau protein in human fluid specimens. Designed for clinical and research laboratories running MagQu's IMR reagent portfolio.
  • MagQuan V Magnetic Concentration Analyzer Rapid magnetic concentration measurement instrument that measures AC magnetization intensity for samples at roughly 30 seconds per sample, covering solid and liquid samples with volumes up to 5 mL without pretreatment. Used by industrial, materials, and research customers for fast magnetic concentration analysis.
  • XacQuan V Frequency-Dependent Magnetic Susceptibility Analyzer Frequency-dependent magnetic susceptibility analyzer that measures real and imaginary components of AC magnetic susceptibility across a 50–24900 Hz bandwidth for analyzing magnetic concentration and material properties. Targeted at industrial QC, materials research, and life science research laboratories.
  • MagQu Amyloid β 1-40 (Aβ1-40) IMR Reagent ImmunoMagnetic Reduction reagent (MF-AB0-006B) for quantitative detection of Amyloid β 1-40 protein in human plasma with an analytical range of 1–200 pg/mL. Uses ~50 nm Fe3O4 magnetic particles conjugated with anti-Aβ1-40 antibodies; assists in the diagnosis of Alzheimer's disease. CE-IVD and Taiwan FDA cleared for IVD use.
  • MagQu Amyloid β 1-42 (Aβ1-42) IMR Reagent ImmunoMagnetic Reduction reagent (MF-AB2-006B) for quantitative detection of Amyloid β 1-42 protein in human plasma with an analytical range of 1–100 pg/mL. Designed to assist in the diagnosis of Alzheimer's disease by detecting a major component of amyloid plaques. CE-IVD and Taiwan FDA cleared for IVD use.
  • MagQu Tau Protein IMR Reagent ImmunoMagnetic Reduction reagent (MF-TAU-006B) for quantitative detection of Tau protein in human plasma with an analytical range of 1–100 pg/mL. Associated with Alzheimer's, Pick's, Parkinson's, and other neurodegenerative conditions. CE-IVD and Taiwan FDA cleared for IVD use.
  • Aβ1-40 Protein Control Solution Low and high concentration quality control solutions used as standards for MagQu's Aβ1-40 IMR Reagent (MF-AB0-006B). Supplied alongside the reagent as part of the clinical IMR assay workflow.
  • Qbeads-Carboxyl Magnetic Beads Carboxyl-functionalized magnetic beads (~1 μm diameter) with a single-crystal Fe3O4 core and dextran coating, used for covalent conjugation of antibodies, proteins, peptides, or DNA via EDC activation. Sold to life science research laboratories for custom assay development.
  • Magnetic Fluid-Carboxyl Nanoparticles Carboxyl-functionalized magnetic nanoparticles (50–60 nm diameter, 8 mg-Fe/mL concentration) with a dextran-coated Fe3O4 core, used for biospecies separation, biomedical imaging, and bioassay development. Supplied to research laboratories and OEM partners.
  • Magdorf Magnetic Separator Eight-well magnetic separator for 1.5 mL microcentrifuge tubes providing strong magnetism for fast collection of micron-size magnetic beads, used in bead-based nucleic acid extraction and immunoprecipitation workflows in research labs.
  • Blood gDNA Extraction Kit Manual genomic DNA extraction kit from blood samples using magnetic particles, providing high-yield, low-cost purified gDNA suitable for Real-Time PCR, PCR, and other molecular experiments. 96 reactions per kit, sold to research and clinical molecular laboratories.
  • Virus DNA/RNA Extraction Kit (manual) Manual extraction kit for viral DNA or RNA from cell-free samples using magnetic particles, with DNA/RNA separable by user-added DNase or RNase. Marketed for in vitro diagnostic use by clinical and research laboratories.
  • Cell Nucleic Acid Extraction Kit Manual extraction kit for total nucleic acids from cells using magnetic particles, yielding purified nucleic acids suitable for Real-Time PCR, PCR, and other molecular experiments. Sold to research laboratories.
  • Qbeads-Carboxyl Labeling Kit Complete kit for covalently conjugating antibodies, peptides, or DNA with primary amine groups onto carboxyl-functionalized Qbeads, used for immunoprecipitation, chromatin immunoprecipitation, and pull-down assays in research laboratories.
  • IMR Assay Kit OEM/ODM Customization Service OEM/ODM customization services for IMR assay kit development, enabling partners to leverage MagQu's IMR platform for their own biomarker assays. Sold to diagnostic and biotech partners.
  • Magnetic Beads OEM/ODM Development Service Custom development of functionalized magnetic beads for OEM/ODM partners, including bead design, surface chemistry, and application-specific conjugation services. Sold to life science and diagnostic partners.
  • Antibody OEM/ODM Service Custom antibody manufacturing and OEM/ODM antibody services for partners, supporting IMR assay and magnetic bead development workflows. Sold to diagnostic and research partners.
  • Magnetic Concentration Quantification Service Contract magnetic concentration measurement service performed by MagQu on customer samples using MagQu's proprietary analyzers, including applications such as lubricant iron content monitoring, magnetic fluid concentration, and steel/powder metallurgy QC. Sold to industrial and research customers.
  • Instrument Customization Service Instrument customization services adapting MagQu's XacPro-S, MagQuan V, XacQuan V, and Magdorf platforms for partner-specific analytical workflows. Sold to OEM/ODM partners and large institutional customers.

Quantifiable outcome

  • 80% clinical accuracy in distinguishing mild cognitive impairment and early Alzheimer's disease patients
  • +4 more outcomes

Companies that use MagQu

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles2 records

MagQu technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

MagQu partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Cerba Research (UK)coreStrategic or Co-development Partner · 1 July 2021Cerba Research, a UK-based clinical research organization, acknowledged the efficacy of MagQu's immunomagnetic reduction (IMR) blood test for diagnosing early Alzheimer's disease in July 2021. The partnership focuses on developing blood-based biomarkers for early diagnosis of Alzheimer's disease, with reference to published studies showing elevated plasma Aβ42 and t-tau levels correlate with later cognitive decline in patients with mild cognitive impairment.
  • European Biotech/Medical Partners (Continental Europe)coreChannel Partner/ Reseller/ DistributorStrategic collaboration with European biotech and medical companies for market entry into continental Europe. The partnership leverages MagQu's CE-IVD certified Alzheimer's blood test products to serve the European clinical diagnostics market. This followed recognition as the world's first CE-IVD certified Alzheimer's blood test and significant international attention from US, European, and Japanese pharmaceutical companies seeking clinical research and commercial partnerships.
  • St. Joseph's Hospital and Medical Center (USA)coreStrategic or Co-development PartnerUS clinical application partnership for neurodegenerative disease blood testing, including development and validation of IMR-based diagnostics in a clinical setting. Plans include establishment of a CLIA-certified reference laboratory for providing IMR blood test services in the US market.
  • Arizona State University (USA)coreStrategic or Co-development PartnerAcademic research collaboration with Arizona State University for clinical research partnerships and application development of neurodegenerative disease blood tests. ASU's research capabilities complement MagQu's IMR technology platform for advancing Alzheimer's disease diagnostics.
  • National Taiwan University Hospital, Shuang Ho Hospital, Renai Hospital, En Chu Kong HospitalcoreStrategic or Co-development PartnerClinical trial partnerships with major Taiwanese medical institutions for validation of Alzheimer's disease blood screening platform. Completed Phase II and Phase III clinical trials involving 400+ patient cases, achieving 80% diagnostic accuracy. Results supported Taiwan FDA (TFDA) registration applications for Class III medical device approval.

Scale indicators6 records

MagQu competitors and assessment

Company assessment

Emerging players

  • PerkinElmer: PerkinElmer's diagnostics and life sciences segments provide biomarker detection reagents and instruments overlapping with MagQu's analyzer and reagent portfolio, particularly in clinical and translational research.
  • ADx NeuroSciences: ADx NeuroSciences develops and licenses high-quality Alzheimer's biomarker antibodies and assays, overlapping with MagQu's IMR reagent portfolio as a focused emerging player in neurodegeneration diagnostics.

Broad incumbents

  • Roche Diagnostics: Roche's Elecsys Alzheimer's disease plasma assays (pTau217, Aβ42) run on the globally installed cobas analyzer base, representing a much larger-scale incumbent that MagQu would compete against for hospital adoption.
  • Siemens Healthineers: Siemens' ADVIA Centaur and Atellica immunoassay platforms address Alzheimer's and oncology biomarker testing through a global installed base, overlapping with MagQu's clinical diagnostic use cases.
  • Bio-Techne: Bio-Techne offers protein biomarker assay kits and magnetic bead-based research reagents through its ProteinSimple and R&D Systems brands, overlapping with MagQu's life-science research and IMR reagent offerings.
  • Abbott Diagnostics: Abbott's ARCHITECT and Alinity immunoassay systems run biomarker panels relevant to neurodegeneration and oncology, representing broad incumbent competition for clinical diagnostic menu share.

Direct peers

  • C2N Diagnostics: C2N's PrecivityAD blood test for Alzheimer's diagnosis is the most direct US-market competitor, and its CLIA-certified reference lab service model parallels MagQu's planned St. Joseph's CLIA partnership strategy.
  • Quanterix: Quanterix's Simoa single-molecule array technology provides ultra-sensitive blood-based biomarker detection, directly comparable to MagQu's IMR platform in pursuit of picomolar-level quantification of neurodegeneration and oncology biomarkers.
  • Fujirebio: Fujirebio's Lumipulse G pTau217/β-amyloid 1-42 plasma assays are FDA-cleared blood-based Alzheimer's diagnostics with overlapping biomarker menu and clinical positioning to MagQu's CE-IVD Alzheimer's reagents.

Regional players

  • Sysmex: Sysmex is a Japan-headquartered diagnostics and life-sciences company with strong Asia-Pacific distribution and a hematology/immunoassay footprint relevant to MagQu's Japan presence and broader Asian commercial strategy.

Market position

Strengths5 records

Weaknesses5 records

Key risks6 records

Key highlights7 records

Customer concentration

MagQu social profiles

Digital presence

MagQu compliance and trust

Trust signal

Compliance9 records

MagQu financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MagQu leadership team

Management profile

Number of profiles

Profiles1 record

MagQu funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MagQu M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MagQu

What does MagQu do?

MagQu develops, manufactures, and sells in-vitro diagnostic (IVD) reagent kits and analyzer instruments built on its proprietary ImmunoMagnetic Reduction (IMR) platform for ultra-sensitive detection of blood biomarkers, including Aβ1-40, Aβ1-42, and Tau protein for early Alzheimer's disease diagnosis. The product portfolio includes CE-IVD and Taiwan FDA-cleared reagent kits, SQUID-based Magnetic Immunoassay Analyzers, magnetic concentration analyzers, functionalized magnetic beads, magnetic separators, and nucleic acid extraction kits sold directly to hospitals, research institutions, and diagnostic laboratories. Custom OEM/ODM services and contract magnetic concentration quantification services supplement the product offering.

Is MagQu a public or private company?

MagQu is a private company. It is classified as unknown and is currently operating.

When was MagQu founded?

MagQu was founded in 2008. It employs 11 to 50 people.

Where is MagQu based?

MagQu is headquartered in New City, United States, in the North America region.

How does MagQu make money?

Five revenue lines are on record. IVD Reagent Sales are the primary driver. The others are analyzer/Instrument Sales, magnetic Beads and Separators, customized Instrument OEM/ODM Services and magnetic Concentration Quantification Service.

Who are MagQu's main competitors?

Emerging players on record are PerkinElmer and ADx NeuroSciences. Broad incumbents are Roche Diagnostics, Siemens Healthineers, Bio-Techne and Abbott Diagnostics. Direct peers are C2N Diagnostics, Quanterix and Fujirebio. Sysmex is listed as a regional player.

Does MagQu have an API?

No public API is recorded for MagQu.

What industry is MagQu in?

MagQu's product category is In Vitro Diagnostics (IVD) and Immunoassay Reagents. Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument), with a secondary code of HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales